Condition: Sickle Cell Anemia (HbSS) · Sickle-β0-thalassemia (HbSβ0) · Sponsor: Children's Hospital Medical Center, Cincinnati
The main reason for this research study is to learn more about hydroxyurea and the treatment of sickle cell anemia (SCA). Hydroxyurea is a medication that has been studied for many years and has been shown to provide benefits for people with SCA. In this research study, the investigators hope to learn more about how to improve the dosing and monitoring of hydroxyurea and learn more about the long-term effects of hydroxyurea over time. Hydroxyurea is usually dosed based only on your weight. Our study will use a new way to select a starting dose that is based on how each patient absorbs hydroxyurea.
This description comes directly from the study's public registry record.
Wendi L. Long, Sr. Regulatory Specialist, BS, CCRC · 513-803-3064 · wendi.long@cchmc.org
Teresa Latham, Research Director, DrPH · (513) 803-7922 · teresa.latham@cchmc.org
Always discuss trial participation with your own doctor first.
| Cincinnati Children's Hospital Medical Center | Cincinnati, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07177300